Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Exploring Long-Term Exercise and Fitness Maintenance Using Group Versus Individual Training in a Diverse Group of Breast Cancer Survivors.

Healthcare (Basel, Switzerland)·2026
Same author

Remote Monitoring of Bioelectrical Impedance in Patients With Breast Cancer-Related Lymphedema: 1-Year Pilot Longitudinal Study.

JMIR biomedical engineering·2026
Same author

Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.

JCO oncology practice·2026
Same author

Integration of the PortionSize Ed App into SNAP-Ed for Improving Diet Quality Among Adolescents in Hawaii: A Randomized Pilot Study.

Nutrients·2025
Same author

Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii.

The breast journal·2025

Related Experiment Video

Updated: Jan 13, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.4K

Examining a Genomic Test in Predicting Extended Endocrine Benefit and Recurrence Risk in a Diverse Breast Cancer

Ho Hyun Lee1, Nicholas Siu-Li1, Ian Pagano2

  • 1Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI 96813, USA.

Current Oncology (Toronto, Ont.)
|October 28, 2025
PubMed
Summary

The Breast Cancer Index (BCI) shows no significant racial differences in predicting extended endocrine therapy (EET) benefits for early-stage hormone receptor-positive breast cancer patients. However, Japanese and Asian/Pacific Islander women had lower recurrence risks.

Keywords:
breast cancerbreast cancer indexextended endocrine benefithormone receptor-positive breast cancerrace/ethnicityrecurrence risk

More Related Videos

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

Related Experiment Videos

Last Updated: Jan 13, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.4K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

Area of Science:

  • Oncology
  • Genomics
  • Epidemiology

Background:

  • Extended endocrine therapy (EET) improves outcomes for early-stage hormone receptor-positive (HR+) breast cancer.
  • The Breast Cancer Index (BCI) assesses recurrence risk and predicts benefits of EET.
  • Racial and ethnic disparities in BCI application require investigation.

Purpose of the Study:

  • To evaluate racial and ethnic variations in Breast Cancer Index (BCI) predictions.
  • To assess BCI's utility across diverse populations with early-stage HR+ breast cancer.

Main Methods:

  • Retrospective analysis of 159 early-stage HR+ breast cancer patients in Hawaii.
  • Inclusion of demographic, tumor characteristics, and BCI scores.
  • Logistic regression to analyze recurrence risk and EET benefit prediction by race/ethnicity.

Main Results:

  • Japanese and other Asian/Pacific Islander patients exhibited lower odds of high recurrence risk compared to Caucasians.
  • Higher recurrence risk correlated with increased likelihood of predicted EET benefit.
  • No statistically significant racial/ethnic disparities were found in EET benefit prediction.

Conclusions:

  • BCI appears applicable across diverse racial and ethnic groups for predicting EET benefits.
  • Observed differences in recurrence risk suggest potential biological or socioeconomic factors.
  • Further research with larger, diverse cohorts is needed to confirm findings and address limitations.